October 21, 2024

Beginning January 1, 2025, Humira (brand) will be removed from BlueCross BlueShield of South Carolina and BlueChoice HealthPlan’s Lowest Net Cost, Exchange and Premium formularies. Adalimumab biosimilars will instead be the preferred products for each of these formularies. Humira biosimilars are designed to be biologically similar to the reference medication and are just as safe and effective.

This new biosimilar strategy provides continued quality of care for patients, guaranteed supply, availability of high-concentration doses, and affordability for patients, including manufacturer copay assistance programs and significant cost reduction for plan sponsors.

*Low list price option
#Optum Rx® has contracted with Amgen to private label the Amjevita/adalimumab product as Nuvaila.

Member experience
Letters will be mailed to members affected by this change. Members should work with their providers to ensure new prescriptions are sent to their pharmacies. Specialty pharmacies can assist members with enrolling in manufacturer assistance programs.

If you have any questions, please contact your representative.

Optum Rx and Amgen are independent companies. Optum Rx provides pharmacy benefit management services on behalf of BlueCross BlueShield of South Carolina and BlueChoice HealthPlan.